This DNR II confers T-cells with the ability to resist the suppressive characteristics of TGF-β, demonstrating improved anti-tumor cytotoxicity in a mouse tumor model overexpressing TGF-β (57). The gene discussed is TGFB1; the disease is neoplasm.